
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Argent Biopharma Limited | LSE:RGT | London | Ordinary Share | AU0000326647 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.00 | 5.00 | 7.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:6187N ReGen Therapeutics PLC 16 July 2003 16 July 2003 ReGen Therapeutics Plc DIRECTOR'S SHAREHOLDING London, UK - 16 July, 2003: ReGen Therapeutics Plc (the "Company") a company developing a treatment for Alzheimer's Disease has today received notification from Percy Lomax the Executive Chairman that he has subscribed for 333,333 new ordinary shares in the placing announced on the 15 July 2003 at 1.5p per new ordinary share. This will bring his total holding in the Company to 1,782,069 ordinary shares representing 0.79 per cent of the company's issued share capital following the placing. For further information, please contact: Andrew Marshall Marshall Robinson Roe Tel No 020 7489 2033 This information is provided by RNS The company news service from the London Stock Exchange END RDSEAAXKFASDEFE
1 Year Argent Biopharma Chart |
1 Month Argent Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions